Dublin, Ireland, September 9th, 2019 – Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced that new data on AUM302, a first-in-class PIM/PI3k/mTOR kinase inhibitor, will be highlighted in a poster presentation at the International Association for the Study of Lung Cancer 2019 World Conference on Lung Cancer (IASLC 2019 WCLC) taking place from September 7-10, 2019 in Barcelona.
The pre-clinical data was generated through a collaboration between Inflection Biosciences and Trinity College Dublin, led by Dr. Kathy Gately, Clinical Senior Lecturer Thoracic Oncology Research at the Trinity Translational Medicine Institute, St. James’s Hospital Dublin. The collaboration is jointly funded by Enterprise Ireland and Inflection Biosciences Ltd. Inflection Biosciences Ltd recently announced that global development and commercialisation rights to AUM302 were granted to AUM Biosciences, Singapore.
Dr. Kathy Gately, who led the research collaboration, commented “The data shows for the first time that PIM kinases are activated in two parallel mechanisms of resistance to EGFR TKIs and highlight a rationale for co-targeting treatment strategies with AUM302 in EGFR mutated NSCLC”.
The details for the poster presentation are as follows:
Poster Title: Co-targeting PIM kinase to overcome MET amplified resistance to EGFR TKIs in NSCLC
Poster Session: P2.03 - Biology
Time & Date: 10.15 am - 6.15 pm; Monday 9, 2019
Presenter: Dr. Kathy Gately
Poster Board No.: 500
Location: Exhibit Hall
The full abstract can be viewed here.
About PIM/PI3 kinase inhibitors
The PI3K/AKT pathway is commonly activated in human cancer. Multiple small-molecule inhibitors have been developed to target PI3K/mTOR or AKT kinases, but the efficacy of these drugs is compromised by the stimulation of compensatory signalling pathways. One example of such compensatory pathways is that driven by PIM kinases, which produce parallel oncogenic signals to AKT and mTOR and share several downstream substrates. Therefore, combined inhibition of such activities in a single molecule might have the potential to achieve better clinical efficacy and prevent/suppress resistance in comparison with classical PI3K/AKT/mTOR inhibitors.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the first-in-class AUM300 series (PIM/PI3K/mTOR inhibitors) partnered with AUM Biosciences, internal programs IBL-202 (PIM/PI3K inhibitor) and the IBL-100 series (selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of treatment resistant solid tumours and haematological malignancies. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com